NotesFAQContact Us
Collection
Advanced
Search Tips
ERIC Number: ED245148
Record Type: RIE
Publication Date: 1983-Jul-21
Pages: 507
Abstractor: N/A
Reference Count: 0
ISBN: N/A
ISSN: N/A
Safety and Efficacy of Over-the-Counter Drug Use by the Elderly. Hearing before the Subcommittee on Health and Long-Term Care of the Select Committee on Aging. House of Representatives, Ninety-Eighth Congress, First Session.
Congress of the U.S., Washington, DC. House Select Committee on Aging.
This document contains the prepared statements and panel testimony from the Congressional hearing on over-the-counter (OTC) drug use by the elderly. Opening statements are given by Representatives Claude Pepper (chairman), Ralph Regula, Mary Rose Oakar, Michael Bilirakis, Tom Lantos, and Hal Daub. Topics which are covered include the incidence and quantity of drug use by the elderly, health risks, adverse reactions, phenylpropanolamine (PPA), consumer protection, and the Federal Drug Administration's (FDA) role in the OTC drug safety and regulation. Testimony of the first panel on OTC drugs, particularly weight reduction medications containing PPA, is given by representatives of the Health Research Group, the National Broadcasting Company, and consumers. Testimony of the second panel on mail fraud schemes perpetrated against senior citizens is given by consumer advocates representing the United States Postal Service, Criminal Investigations and Consumer Protection Divisions, and the Center for Science in the Public Interest. Testimony of the third panel on evaluating the safety and efficacy of various drugs including PPA is given by medical experts from Georgetown, Indiana, Johns Hopkins, and George Washington Universities. Testimony of the fourth and final panel on the safety and efficacy of PPA is given by industry officials from the Thompson Medical Company, Inc., representing the fields of pharmacy, cardiology, sociology, psychology, and medicine. The three appendices contain additional material on medication use/abuse among the Pinellas County, Florida elderly, the FDA list of adverse drug reactions to PPA, the Washington State Board of Pharmacy review of OTC drugs, and prepared statements of panel representatives. (BL)
Publication Type: Legal/Legislative/Regulatory Materials
Education Level: N/A
Audience: Policymakers
Language: English
Sponsor: N/A
Authoring Institution: Congress of the U.S., Washington, DC. House Select Committee on Aging.
Identifiers: Congress 98th; Long Term Care; Nonprescription Drugs; PPA
Note: Some pages are marginally legible due to small print.